Mycoplasma bovis vaccine product
US11679150B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2021 |
| Grant date | Jun 20, 2023 |
| Priority date | — |
| Expiry date | Mar 2, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/543
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to modified Mannheimia haemolytica (M. haemolytica) lktCA gene cluster cassettes, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions. Also described herein are Mycoplasma bovis (M. bovis) protective antigens, compositions comprising such antigens, methods of using such antigens and compositions, and kits comprising such antigens and compositions. Also described herein are modified M. haemolytica lktCA gene cluster cassettes engineered to express M. bovis protective antigens, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.